France

2023 was another eventful year for Stallergenes Greer France with the successful launches of new products and services and the consolidation of leadership positions1, thanks to the engagement of its teams.

New products and services

The year notably marked the launches of Orylmyte®, the Group’s tablet for the treatment of house dust allergy, and iPUMP®, the first connected allergy management assistant, on the French market.

Orylmyte®, the only available allergen immunotherapy (AIT) tablet for house dust mite allergy with dose escalation, acts from the first months of treatment and has demonstrated efficacy on allergic rhinitis symptoms. A year after its launch, the tablet benefits from an important presence in France with a 29% market share in terms of new patient initiation, representing one out of three patients initiating AIT in tablet form for house dust mite allergy.

iPUMP®, the Group’s connected allergy management system developed with Aptar Pharma, aims to improve observance and optimise treatment outcomes for both children from 5 years of age and adults undergoing AIT treatment. More than 1,300 patients are currently using iPUMP® and Stallergenes Greer will soon launch a retrospective study to investigate its potential impact on treatment observance. Beyond this study, the perceptions of patients after six months of use, as well as the feedback and satisfaction rates of physicians, will also be assessed.

Cat allergy, an underserved need

Since its launch, Staloral® Cat 300IR/mL has posted strong and steadily increasing sales, confirming an unmet medical need in the field of allergy to cat dander.

In 2023, we trusted an opinion survey to BVA among 96 French allergy specialists to study allergy management practices for cat dander and the role of AIT. The survey highlighted the specific levers and obstacles to desensitisation for this allergy: allergy to cat dander remains underestimated by allergy specialists and is less commonly treated with AIT with a quarter of allergic patients treated compared to half of patients with house dust mite allergy. Cat dander is a highly pervasive allergen, and it is estimated that half of the people sensitised to cat dander do not own a cat.

OrdoIZZY+, personalised services for patients initiating treatment

In addition to its OrdoIZZY secure website dedicated to patients undergoing allergen immunotherapy, the French affiliate launched OrdoIZZY+, a tailored service for new patients identified by allergy specialists as requiring a personalised programme.

The service was specifically designed for patients initiating AIT for cat or house dust mite allergy. A team of dedicated customer service managers was trained to help patients optimise management of the initiation of their named patient product.

Life-threatening allergies

Stallergenes Greer France is fulfilling its commitment to optimise care for patients with bee and wasp venom allergy and obtained the price of Albey® bee venom and wasp venom specialities, which was published by the French Official Journal in 2023. This opens the way for patients with venom allergies to be cared for not only in a hospital setting but also in the office of their healthcare practitioner thanks to the availability of maintenance dosages in pharmacies, thus optimising convenience for patients during the maintenance phase of their treatment.

The upcoming launch of Albey® combined with the addition of peanut allergy oral immunotherapy Palforzia®, which will be launched on the French market in 2024, opens a new chapter for Stallergenes Greer in France with the treatment of severe allergies and an increased presence in hospitals.

Allergy to cat dander is a potentially severe allergy associated with a risk of asthma. Cat dander is extremely volatile and can be found everywhere in homes, including on clothing, even when cats are not present. Since the allergen can only be eliminated by separating the patient from the pet, which is - as I can easily understand - often unthinkable, being able to offer allergen immunotherapy is a relief for doctors and patients alike when pharmacotherapies or symptomatic treatments are not sufficient.”

Dr. DELPHINE DELALANDE